Moberg Pharma (MOB)

Executive Summary

Moberg Pharma AB is a Swedish pharmaceutical company specializing in commercializing proprietary drug delivery innovations for proven compounds. Its lead asset, MOB-015, is a novel topical treatment for onychomycosis (nail fungus) that has already secured market approval in 13 EU countries and is currently commercialized in Sweden. The drug addresses a large and underserved market, with nail fungus affecting approximately 10% of the global population. Moberg's strategy focuses on leveraging its differentiated formulation to improve efficacy and safety over existing oral and topical treatments, positioning MOB-015 as a potential first-line therapy. With a lean operational model and a validated regulatory pathway in Europe, the company is well-placed to capture significant market share in the coming years. Recent developments indicate that Moberg is advancing its regulatory and commercial expansion plans. The company is actively pursuing approvals in additional European countries and preparing for a US regulatory submission, supported by positive Phase 3 data. Management has also signaled interest in out-licensing or partnering for MOB-015 in major markets to maximize value. With a modest valuation of ~$80 million and a clear path to revenue growth, Moberg Pharma represents an attractive opportunity in the specialty pharmaceutical space. Key near-term catalysts include further EU launches, US FDA filing progress, and potential strategic partnerships.

Upcoming Catalysts (preview)

• Q3 2026MOB-015 regulatory approval in additional EU countries80% success
• Q4 2026US FDA submission for MOB-01560% success
• Q2 2026Partnership or licensing deal for MOB-015 outside Europe50% success